Diametric Capital, LP Tyme Technologies, Inc. Transaction History

Diametric Capital, LP

  • $162 Million
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$0.23 - $0.35 $12,778 - $19,445
55,559 Added 192.26%
84,457 $24,000
Q1 2022

May 16, 2022
BUY
$0.28 - $0.68 $8,091 - $19,650
28,898 New
28,898 $10,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email